Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Gibco™ Mouse IL-31 Recombinant Protein, PeproTech®

Click to view available options
Quantity:
1 mg
10 μg
100 μg
2 μg
250 μg
500 μg
Description
Recombinant Murine IL-31 is a 15.8 kDa protein containing 141 amino acid residues. This product is shipped at ambient temperature. For storage, handling and reconstitution information, please see the lot-specific Certificate of Analysis
Interleukin-31 (IL-31) is a recently discovered T-cell cytokine closely related to IL-6 type cytokines and is preferentially produced by T helper type 2 cells. IL-31 activity is mediated through the ligand-induced oligomerization of a dimeric receptor complex containing IL-31 receptor A and oncostatin M receptor. In response to IL-31 binding, these proteins activate the JAK/STAT and the AKT signaling pathways. RNA levels of IL-31 receptor A and oncostatin M receptor are induced in activated monocytes but are expressed constitutively in epithelial cells. IL-31, when overexpressed in transgenic mice, results in the development of pruritis, alopecia, and skin lesions and in humans may result in atopic dermatitis, suggesting that IL-31 may represent a novel target for antipruritic drug development.

Specifications
Specifications
Accession Number | Q6EAL8 |
For Use With (Application) | Functional Assay |
Formulation | protein with no preservative |
Gene ID (Entrez) | 76399 |
Molecular Weight (g/mol) | 15.8 kDa |
Name | Mouse IL-31 |
Quantity | 1 mg |
Source | E. coli |
Regulatory Status | RUO |
Endotoxin Concentration | <1 EU/ μg |
Show More |
Product Content Correction
The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction